Symlin Related Published Studies
Well-designed clinical trials related to Symlin (Pramlintide Subcutaneous)
Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. [2010.11]
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. [2010.09]
Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. [2010.05]
Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients. [2010.02]
A pilot trial of pramlintide home usage in adolescents with type 1 diabetes. [2009.11]
Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. [2009.09]
Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. [2008.12]
Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. [2008.02]
Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. [2008.01]
The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes. [2007.12]
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. [2007.11]
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. [2007.08]
Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes. [2007.07]
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. [2006.10]
The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. [2005.09]
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. [2005.05]
Properties of pramlintide and insulin upon mixing. [2005.04.15]
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. [2005.03]
Well-designed clinical trials possibly related to Symlin (Pramlintide Subcutaneous)
Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? [2010.05]
Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. [2009.05]
The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. [2005.04]
Other research related to Symlin (Pramlintide Subcutaneous)
Pramlintide and the treatment of diabetes: a review of the data since its introduction. [2011.06]
Primer on pramlintide, an amylin analog. [2011.05]
The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. [2011.02]
The effect of pramlintide acetate on glycemic control and weight in patients with
type 2 diabetes mellitus and in obese patients without diabetes: a systematic
review and meta-analysis. [2011]
Dose accuracy and injection force of disposable pens delivering pramlintide for the treatment of diabetes. [2010.11.01]
The role of pramlintide for weight loss. [2010.03]
Patient reported outcomes in adults with type 2 diabetes on basal insulin
randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. [2010]
Comparison of the post-meal glucose response to different insulin bolus waveforms
in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients. [2010]
Enhanced weight loss following coadministration of pramlintide with sibutramine
or phentermine in a multicenter trial. [2010]
Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. [2009.11]
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. [2009.09]
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. [2009.09]
Solution state structures of human pancreatic amylin and pramlintide. [2009.08]
Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. [2009.06]
Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used. [2009.05]
Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used. [2009.04]
Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. [2009.01]
Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. [2008.12.18]
Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. [2008.10]
Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. [2008.09]
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. [2008]
Pramlintide in the treatment of diabetes mellitus. [2008]
Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin. [2007.08.13]
Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. [2007.08.10]
Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. [2007.08]
Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. [2007.08]
Therapies for diabetes: pramlintide and exenatide. [2007.06.15]
Pramlintide Treatment Reduces 24-Hour Caloric Intake and Meal Sizes, and Improves Control of Eating in Obese Subjects: A 6-Week Translational Research Study. [2007.05.15]
Progressive Reduction in Body Weight Following Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study. [2007.05.15]
Low-dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal-Weight Subjects. [2007.05]
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. [2007.04]
Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. [2007.04]
Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. [2007.02]
Pramlintide in the treatment of diabetes. [2006.12]
Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus. [2006.11]
Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide. [2006.09]
Use of pramlintide: the patient's perspective. [2006.05]
Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. [2006.05]
Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. [2006.05]
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. [2006]
Pramlintide acetate. [2005.11.15]
Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. [2005.10]
Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. [2005.04]
Other possibly related research studies
Endocrinology update 2006. [2006.11]
The role of amylin and related peptides in osteoporosis. [2006.11]
Practical considerations of new drugs: new choices for old problems. [2006.04]
Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. [2006.01]
Obesity drugs in clinical development. [2006.04]
Diabetes: assessing the pipeline. [2006.04]
Clinical studies. [2005]
Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. [2005.12]
Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. [2005.12]
Novel pharmacologic agents for type 2 diabetes. [2005.03]
New therapeutic options for the management of diabetes. [2007.01]
Pharmacologic management of type 1 diabetes: a review for dentistry. [2007.09]
Management of comorbid diabetes and cancer. [2007.07]
Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. [2007.10]
Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. [2008.01]
Insulin-associated weight gain in diabetes--causes, effects and coping strategies. [2007.11]
Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. [2008.05.20]
Pharmacotherapy for obesity. [2007.12]
New therapies for diabetes. [2007]
Approaches to help people with diabetes overcome barriers for improved health outcomes. [2008.01]
Optimizing treatment success with an amylin analogue. [2008.01]
Optimizing diabetes treatment using an amylin analogue. [2008.01]
Management of obesity in patients with type 2 diabetes mellitus. [2007.05]
Gateways to clinical trials. [2007.11]
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. [2007]
Newly approved and promising antidiabetic agents. [2007.07]
Managed care perspective on three new agents for type 2 diabetes. [2008.05]
Type 2 diabetes: the many facets of care. [2008.06]
Twenty-four hour Simultaneous Subcutaneous Basal-Bolus Administration of Insulin and Amylin in Adolescents with Type 1 Diabetes Decreases Post-Prandial Hyperglycemia. [2009.02.03]
New drugs for type 2 diabetes mellitus: what is their place in therapy? [2008]
How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference. [2009.08]
Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. [2009.03]
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. [2009.01.01]
Insulin analog therapy: improving the match with physiologic insulin secretion. [2009.01]
New potential adjuncts to treatment of children with type 1 diabetes mellitus. [2009.04]
[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus] [2008.03]
Adjunct therapy for type 1 diabetes mellitus. [2010.06]
|
